Karin Eastham, a director at Veracyte, Inc. (NASDAQ: VCYT), executed a series of stock sales on June 18, 2026, totaling $197,234. The transactions were carried out under the guidelines of a Rule 10b5-1 trading plan, which Eastham originally established on September 5, 2025. This insider activity takes place as Veracyte's stock trades near its 52-week high of $53.81, following a substantial 103% gain over the past year.
The sales were structured across two distinct transactions. In the initial transaction, Eastham disposed of 3,200 shares at a weighted average price of $52.7832 per share. Individual sale prices within this batch ranged from $52.26 to $53.26. In the second transaction, an additional 529 shares were sold at a weighted average price of $53.5504 per share, with prices for these specific sales ranging from $53.29 to $53.70. Following these dispositions, Eastham directly holds 15,097 shares of Veracyte common stock.
Veracyte, Inc. is a diagnostics company headquartered in South San Francisco, California, with a market capitalization of $4.2 billion. According to InvestingPro analysis, the stock currently appears overvalued relative to its Fair Value. Investors seeking deeper insights can access a comprehensive Pro Research Report on VCYT, available for this and 1,400+ other US equities.
In other recent news, Veracyte, Inc. reported significant developments across various fronts. The company announced the U.S. commercial launch of its Prosigna Breast Risk of Recurrence test, which will be available starting June 8, 2026. This test is designed for early-stage hormone-receptor positive breast cancer patients, estimating the 10-year probability of distant recurrence and predicting chemotherapy benefits. Additionally, Veracyte's TrueMRD Monitoring Test for bladder cancer received Medicare coverage, with availability set for June 1, 2026, aimed at recurrence monitoring in muscle-invasive bladder cancer patients.
On the financial side, Veracyte's stock received mixed analyst attention. Canaccord maintained a Hold rating with a price target of $42 following the presentation of clinical study results, while Wolfe Research initiated coverage with an Outperform rating and a $55 price target. Needham raised its price target to $57 from $48, maintaining a Buy rating due to positive results from the OPTIMA trial. These updates reflect Veracyte's ongoing efforts in expanding its diagnostic offerings and the varied analyst perspectives on its financial prospects.
Veracyte Inc. 53.21▼-0.42(-0.78%) Closed·15:59:59·USD 53.35▲+0.16(+0.30%) After Hours·16:38:44 1D 1W 1M 6M 1Y 5Y Max Created with Highcharts 11.4.8 14:00 15:00 16:00 17:00 18:00 19:00 52 53 54 Analyze VCYT